Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Treatment of CMV Retinitis




 

New England Journal of Medicine (06/18/92) Vol. 326, No. 25, P. 1701

The more toxic side effects and decreased anti-HIV activity of the combination of ganciclovir and zidovudine (AZT) to treat cytomegalovirus (CMV) retinitis could explain the poorer performance of the combination as compared with foscarnet in the study published in the Jan. 23 issue of the New England Journal of Medicine, writes Susan W. Cox and Britta Wahren of the National Bacteriological Laboratory in Stockholm, Sweden. Foscarnet has not only been shown to act synergistically with AZT against the HIV, but also the combination of foscarnet and AZT have reduced toxicity as compared with either drug alone. But ganciclovir has demonstrated increased toxicity synergistically in combination with AZT. Moreover, recent studies in the laboratory have shown that ganciclovir may antagonize the anti-HIV effect of zidovudine, which explains the apparently decreased anti-HIV effect of the combination of ganciclovir and AZT, conclude the researchers.



 


Copyright © 1992 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 18, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.